Mineralocorticoid Receptor Antagonists: A New Sprinkle of Salt and Youth

The document discussed the potential benefits of using mineralocorticoid receptor (MR) antagonists, such as spironolactone, canrenoate, and eplerenone, to mitigate the side effects of topical glucocorticoid (GC) therapy, like skin atrophy and delayed wound healing. It was found that MR antagonists could improve wound healing in diabetic animals by promoting keratinocyte proliferation and targeting epithelial sodium channels. The study suggested that combining MR antagonists with GC therapy might help overcome some GC-induced side effects. Additionally, MR antagonism was shown to enhance re-epithelialization of pathological wounds and increase elastin deposition in human skin, potentially improving skin elasticity and quality. However, further research was needed to fully understand MR's role in skin homeostasis and wound healing, particularly in patients with chronic diseases or diabetes.